Aptevo Therapeutics Inc. reported a net loss of $26.0 million for the year ended December 31 2025, a modest increase from the $24.1 million loss recorded in 2024. Research and development expenses rose slightly to $14.5 million from $14.4 million, while the company’s cash and cash equivalents grew to $21.6 million, up from $8.7 million at the end of 2024. The company also announced a $60 million equity line with Yorkville Advisors Global, providing additional liquidity to support ongoing development activities.
The company’s lead bispecific antibody, mipletamig, delivered encouraging interim data in frontline acute myeloid leukemia (AML) patients. In 28 evaluable patients, mipletamig achieved an 86 % clinical benefit rate (comprising complete remission, complete remission with incomplete blood count recovery, and partial remission) and was associated with no cases of cytokine release syndrome. These results reinforce mipletamig’s potential to improve frontline AML therapy when combined with standard‑of‑care agents.
Aptevo expanded its CD3 portfolio and introduced its first trispecific drug candidates, APVO451 and APVO452, designed to overcome immune suppression in solid tumors. The addition of these trispecific programs broadens the company’s therapeutic reach beyond hematologic malignancies into solid tumor indications, aligning with its strategy to diversify its pipeline.
In a leadership transition, President and CEO Marvin White will step into the role of Executive Chair, while Jeff Lamothe will assume the position of President and Chief Executive Officer. The change is intended to bring fresh executive focus to the company’s growth initiatives while maintaining continuity in strategic direction.
The company’s strengthened cash position and new equity line are expected to support operations through the fourth quarter of 2026, providing a financial cushion for continued clinical development and potential future capital raises.
Management emphasized the significance of the year’s progress: "2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position," said President and CEO Marvin White. "Most importantly, recently reported mipletamig data continue to demonstrate encouraging remission outcomes together with a favorable safety profile, including no cytokine release syndrome observed in frontline patients treated to date. These results support the potential for mipletamig to enhance frontline AML treatment alongside existing standard‑of‑care therapy."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.